AUSTIN, Texas, Feb. 6, 2018 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7th Annual Global Healthcare Conference to be held February 14-15, 2018, in New York, NY. The investor presentation will begin at 10:30 a.m. Eastern time on Thursday, February 15, 2018. The presentation will be webcast live... Read more
Laboratory Automation Solutions Designed to Boost Productivity Showcased at SLAS 2018 SAN DIEGO, Feb. 6, 2018 /PRNewswire/ — SLAS 2018 – Thermo Fisher Scientific, the world leader in serving science, today announced new laboratory automation technologies designed to streamline workflows, optimize productivity, and speed time to results. The new solutions are on display this week... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more
Venlo, The Netherlands, January 31, 2018 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the Company up to a total of US$200 million (or the... Read more
2018 SCIEX Microscale Separations, Innovations Medal and Award will be Presented to Dr. Amy E. Herr, Lester John & Lynne Dewar Lloyd Distinguished Professor of Bioengineering at the University of California, Berkeley at MSB 2018, Rio de Janeiro February 05, 2018 Framingham, MA — SCIEX, a global leader in life science analytical technologies, has announced... Read more
Cambridge, United Kingdom – 25 January 2018 –Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors. Dr Atkins has over 25 years’ experience as a global... Read more
Advanced analytics and remote diagnostics wireless cold storage monitoring solution voted most innovative product of 2017 WALTHAM, Mass., Feb. 1, 2018 /PRNewswire/ — Senior executives in manufacturing operations within large global corporations have selected the Thermo Scientific InSight wireless cold storage monitoring solution as the winner of the 2017 Manufacturing Leaders’ Innovation Award. The InSight wireless monitoring... Read more